Dec. 12, 2024 — Some patients with diabetes develop a serious condition known as diabetic cardiomyopathy, which is slow and cannot be directly attributed to hypertension or other cardiovascular ...

The updated guidelines from the American Diabetes Association emphasize the use of antibody-based screening for type 1 ...

Dilated cardiomyopathy (DCM) is a heterogeneous disorder that is familial in approximately 30% of cases. Although several genes have been identified that can cause familial DCM, molecular analyses ...

The FDA has issued a CRL to Lexicon regarding the NDA for Zynquista (sotagliflozin) as an adjunct to insulin therapy for T1D and CKD.

Type 2 diabetes mellitus substantially increases the lifetime risk of both developing and dying from heart failure. While this appears to be explained in part by the well-known association of ...

Study warns of risks of intense training in young athletes: when does exercise benefit or harm children's hearts?

claiming a green light from the US regulator for mavacamten as a therapy for obstructive hypertrophic cardiomyopathy (HCM). Orally-active mavacamten – which was acquired by BMS when it bought ...

Medically reviewed by Angela Ryan Lee, MD Heart failure occurs when the heart can't pump blood as well as it should. It can ...

Dec. 11, 2024 — Scientists have made a significant breakthrough in understanding how 'bad' cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...